Skip to main content
. 2022 Nov 14;12:1019555. doi: 10.3389/fonc.2022.1019555

Table 1.

General characteristics of patients with oral cavity squamous cell carcinoma enrolled from Hospital 1 and Hospital 2 before (n = 3028) and after (n = 1598) propensity score matching.

Before PS matching After PS matching
Characteristic (n, %; before PS matching) Hospital 1 (n = 2009)n (%) Hospital 2 (n = 1019)n (%) SMD (%) p a Hospital 1 (n = 799)n (%) Hospital 2 (n = 799)n (%) SMD (%)
Margin status (mm) <0.0001
 <5 (1357, 44.8) 693 (34.5) 664 (65.2) -64.44 276 (34.5) 528 (66.1) -66.47
 ≥5 (1671, 55.2) 1316 (65.5) 355 (34.8) 64.44 523 (65.5) 271 (33.9) 66.47
Tumor subsite <0.0001
 Lip (99, 3.3) 74 (3.7) 25 (2.5) 7.14 20 (2.5) 21 (2.6) -0.79
 Tongue (1272, 42.0) 775 (38.6) 497 (48.8) -20.67 368 (46.1) 371 (46.4) -0.75
 Gum (386, 12.7) 267 (13.3) 119 (11.7) 4.88 87 (10.9) 92 (11.5) -1.98
 Mouth floor (129, 4.3) 91 (4.5) 38 (3.7) 4.02 36 (4.5) 35 (4.4) 0.61
 Hard palate (48, 1.6) 24 (1.2) 24 (2.4) -8.8 16 (2.0) 15 (1.9) 0.97
 Buccal (888, 29.3) 625 (31.1) 263 (25.8) 11.77 231 (28.9) 218 (27.3) 3.62
 Retromolar (140, 4.6) 104 (5.2) 36 (3.5) 8.06 27 (3.4) 31 (3.9) -2.68
 Other sites (66, 2.2) 49 (2.4) 17 (1.6) 5.44 14 (1.7) 16 (2.0) -1.84
Sex <0.0001
 Men (2703, 89.3) 1843 (91.7) 860 (84.4) 22.79 702 (87.9) 705 (88.2) -1.16
 Women (325, 10.7) 166 (8.3) 159 (15.6) -22.79 97 (12.1) 94 (11.8) 1.16
Age (years) 0.0003
 <65 (2511, 82.9) 1701 (84.7) 810 (79.5) 13.54 646 (80.9) 662 (82.9) -5.2
 ≥65 (517, 17.1) 308 (15.3) 209 (20.5) -13.54 153 (19.1) 137 (17.1) 5.2
Pathologic T status <0.0001
 T1 (587, 19.4) 328 (16.3) 259 (25.4) -22.51 189 (23.7) 180 (22.5) 2.67
 T2 (962, 31.8) 620 (30.9) 342 (33.6) -5.78 252 (31.5) 262 (32.8) -2.68
 T3 (468, 15.5) 313 (15.6) 155 (15.2) 1.02 137 (17.1) 129 (16.1) 2.69
 T4 (1011, 33.4) 748 (37.2) 263 (25.8) 24.77 221 (27.7) 228 (28.6) -1.95
Pathologic N status 0.0009
 pN0 (1988, 65.7) 1301 (64.8) 687 (67.4) -5.62 546 (68.3) 535 (67.0) 2.94
 pN1 (309, 10.2) 194 (9.7) 115 (11.3) -5.32 93 (11.6) 88 (11.0) 1.97
 pN2 (272, 9.0) 173 (8.6) 99 (9.7) -3.83 64 (8.0) 75 (9.4) -4.89
 pN3 (459, 15.2) 341 (16.9) 118 (11.6) 15.46 96 (12.1) 101 (12.6) -1.9
Pathologic stage <0.0001
 I (518, 17.1) 291 (14.5) 227 (22.3) -20.22 166 (20.8) 159 (19.9) 2.18
 II (705, 23.3) 464 (23.1) 241 (23.7) -1.31 179 (22.4) 187 (23.4) -2.38
 III (465, 15.4) 302 (15.0) 163 (16.0) -2.66 148 (18.5) 130 (16.3) 5.95
 IV (1340, 44.3) 952 (47.4) 388 (38.0) 18.9 306 (38.3) 323 (40.4) -4.36
Tumor differentiation <0.0001
 Well (812, 26.8) 375 (18.7) 437 (42.9) -54.38 286 (35.8) 296 (37.0) -2.6
 Moderately (1902, 62.8) 1359 (67.6) 543 (53.3) 29.69 473 (59.2) 465 (58.2) 2.03
 Poorly (314, 10.4) 275 (13.7) 39 (3.8) 35.43 40 (5.0) 38 (4.8) 1.16
Depth of invasion (mm) <0.0001
 <10 (1554, 51.3) 971 (48.3) 583 (57.2) -17.86 444 (55.6) 436 (54.6) 2.01
 ≥10 (1474, 48.7) 1038 (51.7) 436 (42.8) 17.86 355 (44.4) 363 (45.4) -2.01
Extra-nodal extension 0.0006
 No (2564, 84.7) 1669 (83.1) 895 (87.8) -13.52 706 (88.4) 700 (87.6) 2.31
 Yes (464, 15.3) 340 (16.9) 124 (12.2) 13.52 93 (11.6) 99 (12.4) -2.31
Neck nodal yield <0.0001
 <15 nodes (228, 7.5) 35 (1.7) 193 (18.9) -58.88 35 (4.4) 30 (3.8) 3.17
 ≥15 nodes (2800, 92.5) 1974 (98.3) 826 (81.1) 58.88 764 (95.6) 769 (96.2) -3.17
Treatment modality 0.0075
 S alone (1540, 50.9) 987 (49.1) 553 (54.3) -10.3 466 (58.3) 444 (55.6) 5.56
 S plus adjuvant therapyb
(1488, 49.1)
1022 (50.9) 466 (45.7) 10.3 333 (41.7) 355 (44.4) -5.56

PS, propensity score; S, surgery; CT, chemotherapy; RT, radiotherapy; SMD, standardized mean difference.

aChi-square test; bS plus CT + S plus RT+ S plus CT and RT.